Exploring adipogenic and myogenic circulatory biomarkers of recurrent pressure injury risk for persons with spinal cord injury
Purpose: To investigate linkages between circulatory adipogenic and myogenic biomarkers, gluteal intramuscular adipose tissue (IMAT), and pressure injury (PrI) history following spinal cord injury (SCI).
Methods: This is an observational repeated-measures study of 30 individuals with SCI. Whole blood was collected regularly over 2-3 years. Circulatory adipogenic and myogenic gene expression was determined. IMAT was defined as above/below 15% (IMATd) or percentage (IMAT%). PrI history was defined as recurrent PrI (RPrI) or PrI number (nPrI). Model development used R packages (version 3.5.1). Univariate analysis screened for discriminating genes for downstream multivariate and combined models of averaged and longitudinal data for binary (RPrI/IMATd) and finer scales (nPrI/IMAT%).
Results: For adipogenesis, Krüppel-like factor 4 was the top RPrI predictor together with resistin and cyclin D1, and sirtuin 2 was the top IMAT predictor. For myogenesis, the top RPrI predictor was dysferlin 2B, and pyruvate dehydrogenase kinase-4 was the top IMAT predictor together with dystrophin.
Conclusion: Circulatory adipogenic and myogenic biomarkers have statistically significant relationships with PrI history and IMAT for persons with SCI. Biomarkers of interest may act synergistically or additively. Variable importance rankings can reveal nonlinear correlations among the predictors. Biomarkers of interest may act synergistically or additively, thus multiple genes may need to be included for prediction with finer distinction.
Henzel MK, Bogie KM. Medical management of pressure ulcers in patients with spinal cord disorders. In: Kirshblum S, Lin VW, eds. Spinal cord medicine, 3rd ed. Springer 2018;516-543.
Padula WV, Pronovost PJ, Makic MBF, et al. Value of hospital resources for effective pressure injury prevention: a cost-effectiveness analysis. BMJ Qual Saf. 2019 Feb;28(2):132-141.
Padula WV, Delarmente BA. The national cost of hospital-acquired pressure injuries in the United States. Int Wound J. 2019 Jun;16(3):634-640.
Burns AS, Marino RJ, Flanders AE, Flett H. Clinical diagnosis and prognosis following spinal cord injury. Handb Clin Neurol. 2012;109:47-62.
Edsberg LE, Langemo D, Baharestani MM, Posthauer ME, Goldberg M. Unavoidable pressure injury: state of the science and consensus outcomes. J Wound Ostomy Continence Nurs. 2014 Jul-Aug;41(4):313-334.
Schwartz K, Henzel MK, Ann Richmond M, et al. Biomarkers for recurrent pressure injury risk in persons with spinal cord injury. J Spinal Cord Med. 2019 Sep 6:1-8.
Wu GA, Bogie KM. Not just quantity: gluteus maximus muscle characteristics in able-bodied and SCI individuals--implications for tissue viability. J Tissue Viability. 2013 Aug;22(3):74-82.
Nie L, Chu H, Liu C, Cole SR, Vexler A, Schisterman EF. Linear regression with an independent variable subject to a detection limit. Epidemiology. 2010 Jul;21 Suppl 4:S17-S24.
Lemmer DP, Alvarado N, Henzel K, et al. What lies beneath: why some pressure injuries may be unpreventable for individuals with spinal cord injury. Arch Phys Med Rehabil. 2019 Jun;100(6):1042-1049.
Payton ME, Greenstone MH, Schenker N. Overlapping confidence intervals or standard error intervals: what do they mean in terms of statistical significance? J Insect Sci. 2003;3:34.
Castro MJ, Apple DF Jr, Staron RS, Campos GE, Dudley GA. Influence of complete spinal cord injury on skeletal muscle within 6 mo of injury. J Appl Physiol. 1999 Jan;86(1):350-358.
Marcus RL, Addison O, Kidde JP, Dibble LE, Lastayo PC. Skeletal muscle fat infiltration: impact of age, inactivity, and exercise. J Nutr Health Aging. 2010 May;14(5):362-366.
Yoshiko A, Hioki M, Kanehira N, et al. Three-dimensional comparison of intramuscular fat content between young and old adults. BMC Med Imaging. 2017 Feb 10;17(1):12.
Farkas GJ, Gorgey AS, Dolbow DR, Berg AS, Gater DR. The influence of level of spinal cord injury on adipose tissue and its relationship to inflammatory adipokines and cardiometabolic profiles. J Spinal Cord Med. 2018 Jul;41(4):407-415.
Wang TD, Wang YH, Huang TS, Su TC, Pan SL, Chen SY. Circulating levels of markers of inflammation and endothelial activation are increased in men with chronic spinal cord injury. J Formos Med Assoc. 2007 Nov;106(11):919-928.
Morse LR, Stolzmann K, Nguyen HP, et al. Association between mobility mode and C-reactive protein levels in men with chronic spinal cord injury. Arch Phys Med Rehabil. 2008 Apr;89(4):726-731.
Radulovic M, Bauman WA, Wecht JM, et al. Biomarkers of inflammation in persons with chronic tetraplegia. J Breath Res. 2015 May 14;9(3):036001.
Herman P, Stein A, Gibbs K, Korsunsky I, Gregersen P, Bloom O. Persons with chronic spinal cord injury have decreased natural killer cell and increased toll-like receptor/inflammatory Gene Expression. J Neurotrauma. 2018 Aug 1;35(15):1819-1829.
Hsieh PN, Fan L, Sweet DR, Jain MK. The Krüppel-Like factors and control of energy homeostasis. Endocr Rev. 2019 Feb 1;40(1):137-152. PMID: 30307551; PMCID: PMC6334632.
Eisenstein A, Carroll SH, Johnston-Cox H, Farb M, Gokce N, Ravid K. An adenosine receptor-Krüppel-like factor 4 protein axis inhibits adipogenesis. J Biol Chem. 2014 Jul 25;289(30):21071-21081.
Gomes P, Fleming Outeiro T, Cavadas C. Emerging role of Sirtuin 2 in the regulation of mammalian metabolism. Trends Pharmacol Sci. 2015 Nov;36(11):756-768.
Moreno-Navarrete JM, Petrov P, Serrano M, et al. Decreased RB1 mRNA, protein, and activity reflect obesity-induced altered adipogenic capacity in human adipose tissue. Diabetes. 2013 Jun;62(6):1923-1931.
Li Y, Zou W, Brestoff JR, Rohatgi N, et al. Fat-produced adipsin regulates inflammatory arthritis. Cell Rep. 2019 Jun 4;27(10):2809-2816.e3.
Holness MJ, Zariwala G, Walker CG, Sugden MC. Adipocyte pyruvate dehydrogenase kinase 4 expression is associated with augmented PPARγ upregulation in early-life programming of later obesity. FEBS Open Bio. 2012 Mar 5;2:32-36.
Hogarth MW, Defour A, Lazarski C, et al. Fibroadipogenic progenitors are responsible for muscle loss in limb girdle muscular dystrophy 2B. Nat Commun. 2019 Jun 3;10(1):2430.
Copyright (c) 2020 The Authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to Drug Target Insights agree to publish their articles under the Creative Common Attribution Non Commercial 4.0 (CC-BY-NC 4.0) license, which allows third parties to re-use the work without permission as long as the work is properly referenced and the use is non-commercial.